Literature DB >> 29920641

The Practical Challenges of Diagnosis and Treatment Options in Persistent Pulmonary Hypertension of the Newborn: A Developing Country's Perspective.

Narongsak Nakwan1.   

Abstract

Persistent pulmonary hypertension of the newborn (PPHN) is a complication of several respiratory diseases characterized by an elevation in pulmonary vascular resistance with resultant right-to-left shunting of blood and severe hypoxemia in the neonatal period. PPHN carries a high rate of morbidity and mortality, particularly in limited-resource settings (low-income and/or developing country). Echocardiography remains the gold standard for diagnosis of PPHN. Modern therapies such as inhaled nitric oxide, high-frequency oscillatory ventilation, extracorporeal membrane oxygenation, and/or other pulmonary vasodilators agents can reduce the mortality rate of PPHN. Unfortunately, echocardiography and the use of these modern therapies are often difficult for a medical institution to provide for patients in developing countries, even when a timely diagnosis of PPHN has been made. In this review, the practical challenges of timely diagnosis of PPHN and efficient use of available treatment options faced by pediatricians or neonatologists in limited-resource settings are discussed. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2018        PMID: 29920641     DOI: 10.1055/s-0038-1660462

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  2 in total

1.  Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of Newborn: A Pilot Randomized Controlled Trial.

Authors:  Elsayed Abdelkreem; Shaimaa M Mahmoud; Moustafa O Aboelez; Mohamed Abd El Aal
Journal:  Indian J Pediatr       Date:  2021-01-08       Impact factor: 1.967

2.  Possible association between a polymorphism of EPAS1 gene and persistent pulmonary hypertension of the newborn: a case-control study.

Authors:  Narongsak Nakwan; Surakameth Mahasirimongkol; Nusara Satproedprai; Tassamonwan Chaiyasung; Punna Kunhapan; Cheep Charoenlap; Kamonnut Singkhamanan; Chariyawan Charalsawadi
Journal:  J Pediatr (Rio J)       Date:  2021-10-20       Impact factor: 2.990

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.